Catequentenib is named as an intervention in 3 current clinical trials in our USA, China, UK, Spain and Italy registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Advenchen Laboratories, LLC (1). The most-studied condition is Alveolar Soft Part Sarcoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
NCT03016819 · ClinicalTrials.gov ↗ · Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma
|
Phase 3 | Recruiting | Advenchen Laboratories, LLC | UK, USA, China, Spain, Italy |
|
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
NCT07811297 · Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS)
|
Phase 1/2 | Not yet open | Advenchen Pharmaceuticals, LLC | USA |
|
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
NCT07438886 · ClinicalTrials.gov ↗ · Healthy Volunteer
|
Phase 1 | Not yet open | Advenchen Laboratories Nanjing Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Advenchen Laboratories, LLC | 1 |
| Advenchen Pharmaceuticals, LLC | 1 |
| Advenchen Laboratories Nanjing Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
| Clinical trials in China | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Italy | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, China, UK, Spain and Italy registers name Catequentenib (also registered as AL3818) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in USA, 1 with sites in China, 1 with sites in UK, 1 with sites in Spain and 1 with sites in Italy. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Advenchen Laboratories, LLC (1), Advenchen Pharmaceuticals, LLC (1) and Advenchen Laboratories Nanjing Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Catequentenib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Catequentenib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Catequentenib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.